 |
|
COMMENTS AND OPINIONS
Bleeding Associated With Warfarin Use: Improving Outcomes—Reply
Diane K. Wysowski, PhD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
Several approaches may be taken to decrease the risk of a drug safety hazard. Within its regulatory purview, the Food and Drug Administration can request changes in product information including Warnings and Precautions to educate or remind physicians of drug risk, risk factors, and recommendations to decrease risk. The highest level of drug warning is the boxed ("black box") warning, which is appropriate for bleeding due to warfarin use because of its prevalence and serious consequences. A Medication Guide aimed at educating and reminding patients about the risk of bleeding with warfarin use and actions they can take to decrease this risk is also appropriate. While Medication Guides have acknowledged weaknesses including unknown or poor reading rates and, in some cases, poor reader comprehension, they are meant to aid rather than replace discussions between health practitioners and patients about the drug's safe use. The . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Bleeding Associated With Warfarin Use: Improving Outcomes
Megan Barkell
Arch Intern Med. 2008;168(2):236-237.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Bleeding Complications With Warfarin Use: A Prevalent Adverse Effect Resulting in Regulatory Action
Diane K. Wysowski, Parivash Nourjah, and Lynette Swartz
Arch Intern Med. 2007;167(13):1414-1419.
ABSTRACT
| FULL TEXT
|
